Study details
Enrolling now
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Baylor College of Medicine
NCT IDNCT02917083ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
60
Study length
about 23 years
Ages
12–75
Locations
2 sites in TX
About this study
This trial is testing a new treatment called CD30 CAR T cells for people with lymphoma that has returned after other treatments. The goal is to see if these modified T cells can better kill cancer cells and improve outcomes.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take CAR T Cells
PhasePhase 1
DrugCAR T Cells
Primary goalNumber of Patients with Dose-Limiting Toxicities (DLT)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low14%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
cell therapy (Engineered T-cells that target specific cancer antigens)
Endpoints
Primary: Number of Patients with Dose-Limiting Toxicities (DLT)
Secondary: Overall Response Rate
Body systems
Oncology